CBB1003CAS# 1379573-88-2 |
- CI994 (Tacedinaline)
Catalog No.:BCC2159
CAS No.:112522-64-2
- Tubastatin A HCl
Catalog No.:BCC3877
CAS No.:1310693-92-5
- M344
Catalog No.:BCC2162
CAS No.:251456-60-7
- AR-42 (OSU-HDAC42)
Catalog No.:BCC2161
CAS No.:935881-37-1
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 1379573-88-2 | SDF | Download SDF |
| PubChem ID | 57345268 | Appearance | Powder |
| Formula | C25H31N9O4 | M.Wt | 521.57 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble in DMSO | ||
| Chemical Name | 4-[[3-[4-(4-carbamimidoylbenzoyl)piperazine-1-carbonyl]-5-nitrophenyl]methyl]piperazine-1-carboximidamide | ||
| SMILES | C1CN(CCN1CC2=CC(=CC(=C2)C(=O)N3CCN(CC3)C(=O)C4=CC=C(C=C4)C(=N)N)[N+](=O)[O-])C(=N)N | ||
| Standard InChIKey | SKTVJNLOILHEKO-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C25H31N9O4/c26-22(27)18-1-3-19(4-2-18)23(35)31-9-11-32(12-10-31)24(36)20-13-17(14-21(15-20)34(37)38)16-30-5-7-33(8-6-30)25(28)29/h1-4,13-15H,5-12,16H2,(H3,26,27)(H3,28,29) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
CBB1003 Dilution Calculator
CBB1003 Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.9173 mL | 9.5864 mL | 19.1729 mL | 38.3458 mL | 47.9322 mL |
| 5 mM | 0.3835 mL | 1.9173 mL | 3.8346 mL | 7.6692 mL | 9.5864 mL |
| 10 mM | 0.1917 mL | 0.9586 mL | 1.9173 mL | 3.8346 mL | 4.7932 mL |
| 50 mM | 0.0383 mL | 0.1917 mL | 0.3835 mL | 0.7669 mL | 0.9586 mL |
| 100 mM | 0.0192 mL | 0.0959 mL | 0.1917 mL | 0.3835 mL | 0.4793 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Arillatose B
Catalog No.:BCN6196
CAS No.:137941-45-8
- ML 239
Catalog No.:BCC3987
CAS No.:1378872-36-6
- 6-O-Feruloylglucose
Catalog No.:BCN6195
CAS No.:137887-25-3
- Valsartan methyl ester
Catalog No.:BCC9189
CAS No.:137863-17-3
- Valsartan
Catalog No.:BCC5017
CAS No.:137862-53-4
- 2,3-Di(3',4'-methylenedioxybenzyl)-2-buten-4-olide
Catalog No.:BCN1576
CAS No.:137809-97-3
- Boeravinone E
Catalog No.:BCN4083
CAS No.:137787-00-9
- 12-O-Acetylrosmarinine
Catalog No.:BCN2125
CAS No.:137760-53-3
- 7-Methoxy-beta-carboline-1-propionic acid
Catalog No.:BCN2995
CAS No.:137756-13-9
- 9-Methoxycanthin-6-one-N-oxide
Catalog No.:BCN2994
CAS No.:137739-74-3
- BIM 187
Catalog No.:BCC5933
CAS No.:137734-88-4
- GR 64349
Catalog No.:BCC5800
CAS No.:137593-52-3
- CBB1007
Catalog No.:BCC4272
CAS No.:1379573-92-8
- Dehydrotolvaptan
Catalog No.:BCC8932
CAS No.:137973-76-3
- Mozavaptan
Catalog No.:BCC5095
CAS No.:137975-06-5
- Atroscine
Catalog No.:BCN1941
CAS No.:138-12-5
- Mafenide
Catalog No.:BCC5237
CAS No.:138-39-6
- D-(-)-Salicin
Catalog No.:BCN6298
CAS No.:138-52-3
- Picrocrocine
Catalog No.:BCC8232
CAS No.:138-55-6
- Shikimic acid
Catalog No.:BCN6200
CAS No.:138-59-0
- Limonene
Catalog No.:BCN3797
CAS No.:138-86-3
- Decorticasine
Catalog No.:BCN2006
CAS No.:1380-03-6
- BET bromodomain inhibitor
Catalog No.:BCC6426
CAS No.:1380087-89-7
- KB SRC 4
Catalog No.:BCC6253
CAS No.:1380088-03-8
CBB1003, a lysine-specific demethylase 1 inhibitor, suppresses colorectal cancer cells growth through down-regulation of leucine-rich repeat-containing G-protein-coupled receptor 5 expression.[Pubmed:25060070]
J Cancer Res Clin Oncol. 2015 Jan;141(1):11-21.
PURPOSE: Lysine-specific demethylase 1 (LSD1) was highly expressed in several malignancies and had been implicated in pathological processes of cancer cells. However, the role of LSD1 in colorectal cancer (CRC) carcinogenesis, prognosis and treatment remains uncharacterized. METHODS: In this study, we examined LSD1 expression in paraffin-embedded CRC specimens from 295 patients, including 65 patients with paired samples of colorectal carcinoma, adjacent adenoma and normal colorectal tissues. Using an LSD1 inhibitor, CBB1003, as a probe, we studied the association between LSD1 and leucine-rich repeat-containing G-protein-coupled receptor 5 (LGR5), a CRC stem cell marker involved in carcinogenesis. The anti-tumor effects of CBB1003 on CRC cells were also examined. RESULTS: LSD1 expression was significantly elevated in colorectal tumor tissues compared with adjacent adenoma and normal colorectal tissues (P < 0.001), and LSD1 levels were significantly correlated with an advanced AJCC T stage (P = 0.012) and distant metastasis (P = 0.004). CBB1003 inhibited CRC cell proliferation and colony formation. In cultured CRC cells, inhibiting LSD1 activity by CBB1003 caused a decrease in LGR5 levels while overexpression of LGR5 reduced CBB1003-induced cell death. We also observed the inactivation of beta-catenin/TCF signaling after CBB1003 treatment, consistent with the positive correlations among LSD1, LGR5, beta-catenin and c-Myc expression in human colon tumor and adenoma tissues. CONCLUSION: Our result suggested that LSD1 overexpression promotes CRC development and that the LSD1 inhibitor inhibits CRC cell growth by down-regulating LGR5 levels and inactivates the Wnt/beta-catenin pathway. Thus, LSD1 and its inhibitor might provide a new target or a useful strategy for therapy of CRC.
